Vista Pharmaceuticals (BOM:524711) Payments of Debt: ₹0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524711 Vista Pharmaceuticals Ltd BOM:524711
48 GF Score
Price ₹6.28
GF Value ₹4.49
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Vista Pharmaceuticals Payments of Debt?

Vista Pharmaceuticals BOM:524711 +0.64% 48 Payments of Debt is ₹0.00 Mil as of Jun. 2026. GuruFocus rates BOM:524711 with a GF Score™ of 48/100 and a GF Value™ of ₹4.49 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Vista Pharmaceuticals's Payments of Debt for the three months ended in Jun. 2026 was ₹0.00 Mil.

Vista Pharmaceuticals's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0.00 Mil.

Vista Pharmaceuticals Payments of Debt Related Terms

Vista Pharmaceuticals Payments of Debt Historical Data

* Premium members only.

The historical data trend for Vista Pharmaceuticals's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vista Pharmaceuticals Payments of Debt Chart

Vista Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -25.92 -22.47 -5.60 -5.36

Vista Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:524711
48GF Score
Vista Pharmaceuticals Ltd BOM:524711
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vista Pharmaceuticals Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of ₹0.00 Mil mean?
Vista Pharmaceuticals (BOM:524711) has a Payments of Debt of ₹0.00 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Vista Pharmaceuticals and its competitors.
Is Vista Pharmaceuticals' Payments of Debt too high?
Vista Pharmaceuticals' current Payments of Debt is ₹0.00 Mil. Overall, Vista Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vista Pharmaceuticals' Payments of Debt compare to ZTS?
Vista Pharmaceuticals' Payments of Debt of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Vista Pharmaceuticals and its competitors. Vista Pharmaceuticals's current Payments of Debt is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vista Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vista Pharmaceuticals (BOM:524711) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹4.49, compared to a current price of ₹6.28 — trading 39.9% above its estimated fair value. The current Payments of Debt is ₹0.00 Mil. Vista Pharmaceuticals' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Vista Pharmaceuticals (BOM:524711), the current Payments of Debt is ₹0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vista Pharmaceuticals (BOM:524711) Overvalued in 2026?

Based on GuruFocus' analysis, Vista Pharmaceuticals stock appears to be overvalued. The current stock price of ₹6.28 is trading 39.9% above its estimated GF Value™ of ₹4.49. GuruFocus considers Vista Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524711:

  • Payments of Debt: ₹0.00 Mil
  • GF Value™: ₹4.49 vs. price of ₹6.28 (39.9% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the BOM:524711 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vista Pharmaceuticals Business Description

Address Kakateeya Hills, Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet, Hyderabad, TG, IND, 500033
Vista Pharmaceuticals Ltd is an Indian company engaged in a single operating segment, which is the manufacturing of Pharmaceutical products. The company offers over-the-counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, and Indomethacin are the drugs offered by the company in a capsule dosage form. The company generates all of its operating revenue from sales within its domestic market.
48GF Score

Get the complete analysis for BOM:524711

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6.28
Price
₹4.49
GF Value